Suchergebnisse - (Subject:"PARP inhibitor")

PubPharm (11)

1

Poly ADP-ribose polymerase (PARP) inhibitors - new therapeutic strategies in Acute Myeloid Leukemia: a literature review

in: Journal of Education, Health and Sport | 2022

von Emilia Nowicka | Michał Obel | Kinga Panuciak | +5

2

Experience with olaparib in a patient with luminal HER2-positive metastatic breast cancer

in: Медицинский совет | 2022

von L. V. Bolotina | A. L. Kornietskaya | A. A. Kachmazov | +5

3

Olaparib maintenance therapy after frontline chemotherapy in patients with BRCA-mutated ovarian cancer: real-world results in expanded access program

in: Медицинский совет | 2022

von A. A. Rumyantsev | A. S. Tyulyandina | I. A. Pokataev | +4

4

in: Onkourologiâ | 2021

von A. I. Stukan | A. Yu. Goryainova | N. A. Riger | +4

5

Clinical significance of mutations in DNA repair genes in patients with metastatic prostate cancer

in: Onkourologiâ | 2021

von O. A. Mailyan | A. S. Kalpinskiy | I. V. Reshetov | +5

6

Experience in treating BRCA-associated breast cancer. The BRCA-history of a family

in: Медицинский совет | 2021

von A. V. Sultanbaev | K. V. Menshikov | A. F. Nasretdinov | +5

7

Novel therapeutic strategies for patients with metastatic triple-negative breast cancer

in: Современная онкология | 2021

von Inna P. Ganshina | Olga O. Gordeeva | Mariam Sh. Manukian

8

Olaparib in the metastatic HER2-negative breast cancer setting

in: Медицинский совет | 2020

von L. G. Zhukova | E. I. Khatkova | I. P. Ganshina | +2

9

Russian multicenter experience of using talazoparib in the treatment of patients with BRCA-associated metastatic breast cancer

in: Медицинский совет | 2020

von T. Yu. Semiglazova | E. V. Lubennikova | L. V. Bolotina | +20

10

PARP INHIBITORS IN OVARIAN CANCER: TOXICITY PROFILE

in: Медицинский совет | 2017

von S. V. KHOKHLOVA | O. A. SHILKINA